We help you to identify specific procedures, diagnosis trends and actual spend by NHS Hospitals in England. Combined with our bespoke business plans, economic sales tools and knowledge of NHS Procedure Reimbursement and Policy, Device Access gives you the knowledge and abilities to work collaboratively and successfully with both clinical and non-clinical stakeholders within the NHS Hospitals and Clinical Commissioning Groups (CCG’s). We also assist in private sector hospital and insurance reimbursement.
The National Institute for Health and Care Excellence (NICE) is recognised as the Worlds Leading HTA. In 2010 NICE brand new programmes were commissioned for specific evaluation of MedTech Devices and Diagnostics. NICE are always interested in hearing about new MedTech Devices and Diagnostics for the benefit of patients and the healthcare system. We assist many MedTech and Diagnostic companies in successful engagement within these new programmes, which have led to NICE Technology Appraisal (TA) Interventional Procedures (IP) Diagnostic Appraisal Programme (DAP) and MedTech (MTG) guidance.
The NHS Spends $18m a day on research and there are opportunities for MedTech and Diagnostic organisations for clinical evidence development with the National Institute for Heath Research (NIHR). The 8 National Health Technology Cooperatives (HTC’s) are also available for research in specific clinical areas. The NIHR and National Office For Clinical Research Infrastructure (NOCRI) make it fast and easy for MedTech and Diagnostic companies to deliver investigator lead and collaborative clinical research on time and on budget and target. Device Access is here to help you get started.
The UK offers huge potential for innovative medical devices. Access a growing market with world-class resources, academic institutions and a clinical research infrastructure designed to prove concepts.
Despite a difficult economic climate in which other sectors have struggled, the UK Medical Technology sector has rapidly grown in recent years with an increase in turnover of 50% between 2009 and 2012.
Treating almost 1 million patients a day the NHS is a mature organisation with an established supply chain, and a strong appetite for clinical research and the adoption of medical innovations.
Treating almost 1 million patients a day the NHS is a mature organisation with an established supply chain and a strong appetite for proven innovation.
The potential is huge but navigating your way through the development pathway can be quite daunting. We have years of experience and insight plus access to realtime data that can really guide the way.
Device Access UK Ltd (Michelmersh, Romsey UK) NHS Market Access and Reimbursement Consultancy for Medical Devices and Diagnostics, is delighted to announce that it has been granted a licence to access NHS patient data stored by the Health and Social Care Information Centre (HSCIC) – the National provider of information, data and IT systems for commissioners, analysts and clinicians in health and social care
Michael Branagan-Harris, Device Access’s CEO, says: “The award of this licence is a significant milestone for our clients and helps demonstrate a close working relationship with NHS bodies developed over almost 5 years.
“Our services include helping National and International clients take Medical technological devices and diagnostics to the NHS through the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programmes (MTEP), for discussions around the introduction, evaluation and adoption of these technologies. The next step with NICE is a formal submission for them to ultimately consider issuing guidance on the new technology use in the NHS. As part of this process it is vitally important for our clients to be able to demonstrate and identify clear improvements to patient treatment, including diagnosis, admission, interventions performed and hospital stay; thus highlighting the benefit of technology adoption to patients, hospitals and the NHS. We are now able to offer this invaluable service to support these applications.
“We have been granted access to anonymised (patient unidentifiable) data to examine patient pathways from primary care referral to treatment episodes in secondary care. This enables us to view the procedures and treatments they have had, discover what the patients were diagnosed with (and any comorbidities), thus leading to a greater understanding of what these episodes cost the NHS. We have a licence and access to 3 years’ historical data, and are absolutely delighted and extremely grateful to receive the licence from HSCIC.”
Richard Tuson, Device Access’s Health Analytics and Policy Specialist, adds: “We can use this data to conduct analysis to identify within every health economy, (including hospitals and Clinical Commissioning Group areas), where medical technological devices can be used by NHS providers in patient care pathways to improve patient outcomes and reduce the length of stay; patient waiting times and diagnostic waiting times. This all helps to drive efficiency in the NHS.
“We have ICD-10 (diagnosis) OPCS 4.7 (Intervention) and HRG level (Spend), for NHS England, by Hospital and Clinical Commissioning Group (CCG) level which is refreshed every month to allow us to analyse procedure trends and hospital activities over periods of time and identify specific volumes and cohorts of patients that attend follow ups, and how many are readmitted within 30 and 60 plus days.’’
Michael Branagan-Harris concludes: “We are excited to be using this patient pathway data to formulate strategies with our clients to assist them with the introduction of Medical Technological devices. This supports NHS England’s 5 year strategy and ultimately helps speed the adoption and diffusion of Medical Technology innovation for the benefit of NHS patients’’
The analysis shows that around 13% of clinical commissioning groups (CCGs), 37% of relevant providers by number, and 75% of relevant providers by share of supply, objected to the proposed method for determining national prices for NHS services.
Under the legislation governing the NHS payment system, the proposals cannot be introduced if the proportion of CCGs, or the proportion of relevant providers (by number or weighted by share of supply), who object to the method equals or exceeds 51%, unless there is a reference to the Competition and Markets Authority.
As the share of total tariff income received by the objecting providers exceeds 51%, the National Tariff cannot be introduced in its current form at this stage and its implementation will be delayed.
Monitor and NHS England are now considering the feedback received from the consultation and possible next steps, in the context of what the legislation permits in the event that an objection threshold is breached.
Amongst the options available are engaging with the sector then re-consulting on revised proposals or referring the method to the Competition and Markets Authority.
Meanwhile, commissioners and providers will be expected to continue planning for 2015/16 on the basis of the timetable and guidance that has already been issued.
The aim is to raise awareness of persistent heartburn for 3 weeks or more as a symptom of stomach and oesophageal cancers.
Early diagnosis of these diseases is vital, and there’s a great potential in the pharmacy environment to capture people who are asking for advice on how to treat symptoms of persistent heartburn or who are regularly purchasing over-the-counter medicines to treat heartburn.
DH will provide a briefing sheet for pharmacists to help support the campaign along with posters, leaflets and symptom cards. To order free campaign materials (including accessible versions), visit https://www.orderline.dh.gov.uk or call 0300 123 1002.
The £100 million fund is open to bids from GPs wanting to extend access to GP services through improvements such as offering weekend appointments and longer opening hours.
The report issues a call to action to politicians and health service leaders urging them to take more effective steps on preventable diseases.
Time to move from talk to action on reducing preventable illness.
A report by The Richmond Group of Charities
Public Health England’s (PHE) National Cardiovascular Intelligence Network (NCVIN) published its first cardiovascular disease profiles for each of the 211 clinical commissioning groups (CCGs) in England today (5 August 2014). The profiles highlight important facts about these conditions and include information on the leading risk factors such as smoking and obesity.
Following the recommendations of the Cardiovascular Disease Outcomes Strategy to treat coronary heart disease, diabetes, kidney disease and stroke as a single family of conditions, the profiles bring together information about each of these.
Cardiovascular disease is the biggest killer of adults after cancer and is a common reason to premature death. Over recent decades much has already been achieved in reducing the number of people dying from these conditions but many people still experience a reduced quality of life as a result or die prematurely. In 2012 it was recorded that 33,258 people died from heart disease, stroke or vascular disease under the age of 75 years. By using these profiles local areas can identify opportunities for further improvement, building on their success to date while planning to tackle emerging issues such as an aging population and increased levels of obesity.
In coming weeks, as well as the profiles PHE will release an interactive version of the data which allows CCGs to compare themselves with others, including those in their strategic clinical network (SCN). The interactive version of the data will be available in PHE’s Fingertip tool.
The NCVIN is 1 of 5 intelligence networks, with others looking at cancer, mental health dementia and neurology, child and maternal health and end of life. Hosted by PHE, the networks operate across organisations including NHS England, the National Institute for Health and Care Excellence (NICE), local authorities, charities, academic institutions and others. Their aim is to encourage the use of data and information to improve the quality of care and outcomes for communities, patients and their families.
Visit PHE’s data and knowledge gateway to access data and analysis tools from across the organisation.
Standards for surgical practice and achieving high-quality care outlined in new Good Surgical Practice
published by RCS.The Royal College of Surgeons of England today launched Good Surgical Practice outlining clear standards expected of all surgeons.
The guide outlines the skills, values and attitudes that underpin the profession and has been developed with surgeons and patient groups.Good Surgical Practice has been updated following the recent release of the General Medical Council’s re-working of Good Medical Practice and addresses some of the key challenges facing the profession today.
Collaborative working and patient safety shines through as a core message in the guide. In light of the launch of revalidation for all doctors at the beginning of this year, the publication of the Francis Inquiry report in 2013 and increasing focus on quality of care, transparency and professionalism,the guide recommends surgeons should ensure they are effectively working in multidisciplinary teams to improve communication with patients and the decision making process.
Surgical leadership and teamwork are crucial for achieving high-quality patient care and this guide provides surgeons with a model that they should aspire to in day to day practice.
Good Surgical Practice provides guidance around 4 core areas which reflect the four domains of the GMC’s Good Medical Practice:
– Knowledge, skills and performance
– Safety and Quality
– Communication, partnership, teamwork
– Maintaining trust
Miss Clare Marx, President of the Royal College of Surgeons (RCS) said:
Good Surgical Practice is an essential resource for anyone in the profession throughout their careers, as they seek to deliver the best possible outcomes for patients. Surgeons need to be supported to navigate the challenges faced by the profession and deliver the best quality care possible. We should all aspire to the standards outlined in this guide and continue to work together effectively across teams and specialties in the delivery of care.
Miss Clare Marx will be presenting Good Surgical Practice to staff at UHSM, Wythenshawe, Manchester on 10 September 2014.
Access the full copy of Good Surgical Practice here
The NHS terms and conditions are for the use of NHS bodies procuring goods and services from commercial organisations, not for the procurement of clinical services from other NHS bodies or independent sector providers.
This suite of documents provides guidance notes and associated documentation for contract version and framework agreements for the supply of goods and provision of services.
Link to the PDF documents https://www.gov.uk/government/publications/nhs-standard-terms-and-conditions-of-contract-for-the-purchase-of-goods-and-supply-of-services
Do robots improve surgical techniques? https://t.co/439IyTM9O0
- Thursday May 12 - 5:25pm
NHS pushes forward with ambition to create world class cancer services https://t.co/QKzp3aoT6I
- Thursday May 12 - 5:22pm
How Medtech Firms Can Become Better Hospital Partners https://t.co/By4b8E9LfE
- Wednesday May 11 - 8:54am
How can the MedTech Industry engage differently to help the NHS? - Free publication from Beyond Target Magazine https://t.co/XJIk3nFimy
- Friday May 6 - 3:43pm
New NHS centre recruits first patient to world leading genomics project https://t.co/stEmmcnvxY
- Thursday Apr 14 - 5:22pm